[Table/Fig-3]:
Drug | LA | LH | Dyslipidaemia | Insulin resistance |
---|---|---|---|---|
Stavudine (d4T) | +++ | ++ | ++ | ++ |
Zidovudine (AZT) | ++ | + | + | ++ |
Didanosine (DDI) | +/- | +/- | + | + |
Lamivudine (3TC) | 0 | 0 | + | 0 |
Abacavir (ABC) | 0 | 0 | + | 0 |
Tenofovir (TDF) | 0 | 0 | 0 | 0 |
Emtricitabine (FTC) | 0 | 0 | 0 | 0 |
Efavirenz (EFV) | +/- | +/- | HDL<++ | + |
Nevirapine (NVP) | 0 | 0 | HDL<+ | 0 |
Ritonavir (RTV) | +/- | + | +++ | ++ |
Indinavir (IDV) | +/- | + | + | +++ |
Lopinavir (LPV) | +/- | + | ++ | ++ |
Saquinavir (SQV) | +/- | + | +/- | +/- |
Atazanavir (ATV) | 0 | ++ | +/- | 0 |
Darunavir (DRV) | 0 | + | +/- | +/- |
Enfuvirtide (INN) | Insufficient data | Insufficient data | 0 | 0 |
Maraviroc (MVC) | Insufficient data | Insufficient data | 0 | 0 |
Raltegravir (RAL) | Insufficient data | Insufficient data | 0 | 0 |